Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Cadila Healthcare: Take care - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • May 3, 2001

    Cadila Healthcare: Take care

    Cadila Healthcare Ltd. results are below our expectations. Though, year on year basis sales have grown by 6.5% (expected 10.5%), it has infact showed a negative growth (2.7%) on a sequential basis. Operating margins have dipped from 18% in Q3FY01 to a paltry 5.9% in Q4FY01. The sudden drop in operating margins is unexplained at this point of time. Thanks to substantial reduction in interest cost and income from parking of IPO funds, bottomline showed an apparent growth of 64%.

    (Rs m) FY00 FY01 Change 3QFY01 4QFY01 Growth**
    Sales 4,778 5,088 6.5% 1171 1139 -2.7%
    Other Income 74 74 0.0% 25 -8 -132.0%
    Expenditure 4,088 4,351 6.4% 960 1072 11.7%
    Operating Profit (EBDIT) 690 737 6.8% 211 67 -68.2%
    Operating Profit Margin (%) 14.4% 14.5% 0.3% 18.0% 5.9% -67.4%
    Interest 213 (46) -121.6% 0 (57) -
    Depreciation 99 149 50.5% 44 24 -45.5%
    Profit before Tax 452 708 56.6% 192 92 -52.1%
    Tax 53 55 3.8% 18 11 -38.9%
    Profit after Tax/(Loss) 399 653 63.7% 174 81 -53.4%
    Net profit margin (%) 8.4% 12.8%   14.9% 7.1%  
    No. of Shares (eoy) (m) 60 60   60 60  
    Diluted Earnings per share* 6.7 10.9   11.6 5.4  
    P/E (at current price) 15.1 9.3        
    (*- annualised)            
    **- Sequential Growth            

    In a related development , the company recently acquired a 27.7% stake in German Remedies at a cost of Rs 1.49 bn. The acquisition was effectively valued at 2.4 times German Remedies sales. It also acquired perpetual rights to market five leading brands from Asta (one of the promoter of German Remedies). The financing of the same would be done through a mix of debt (Rs 2,000 m) and internal accruals. The company expects to leverage this acquisition to enter high margin therapeutic segments like respiratory, gynaecology and oncology, where German Remedies has a strong presence.

    Particulars Cadila Sun Pharma Cipla
    CMP (Rs.) 101 550 1,127
    Sales (In Rs. Mn) 5,088 6,132 10,477
    Growth (YoY) 6.5% 28.1% 38.0%
    Operating Profit Margins 14.5% 24.6% 20.6%
    P/e (FY 2001) (x) 9.3 19 38
    Market Capitalisation (In Rs Mn) 6,060 24,853 67,577
    Market Cap/Sales (x) 1.2 4.1 6.5

    At the current market price of Rs 101, the stock is valued at 9.3 times its FY01 earnings and 1.2 times its current market capitalisation to sales. The prospects of the company would depend on how fast the ambitious acquisitions pays off. The company also needs to gear up growth, particularly given the fact that its peers like Sun Pharma are growing at much faster rates.



    Equitymaster requests your view! Post a comment on "Cadila Healthcare: Take care". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 21, 2017 (Close)


    • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks



    Detailed Quarterly Results With Charts